Bowman-Birk inhibitor concentrate (BBIC)	baseline	The mean normalized AUC values for the first phase	21234	21428	For the first phase I trial, the normalized AUC for the serum BBI level was moderately correlated with the BBIC dose, with a correlation coefficient of 0.65 and a slope value of 0.0007 (Fig. 3).
Bowman-Birk inhibitor concentrate (BBIC)	baseline	The mean normalized AUC values for the first phase	21636	21735	The difference among the treatment groups was statistically significant (P=0.006 by one-way ANOVA).
Bowman-Birk inhibitor concentrate (BBIC)	placebo	The mean normalized AUC values for the first and second clinical trials	22715	22927	The mean normalized AUC value for BBIC-treated subjects (all doses combined) was 1.808 and 1.325 for the first and second clinical trials, respectively, and the difference was statistically significant (P=0.031).
Bowman-Birk inhibitor concentrate (BBIC)	placebo	The mean normalized AUC values for the first and second clinical trials	22715	22926	The mean normalized AUC value for BBIC-treated subjects (all doses combined) was 1.808 and 1.325 for the first and second clinical trials, respectively, and the difference was statistically significant (P=0.031)
Bowman-Birk inhibitor concentrate (BBIC)	placebo	The mean normalized area under the curve (AUC) values for the second phase	21737	21933	For the second phase I trial, the normalized AUC for the serum BBI level was only weakly correlated with the BBIC dose, with a correlation coefficient of 0.36 and a slope value of 0.0003 (Fig. 3).
Bowman-Birk inhibitor concentrate (BBIC)	baseline	The mean normalized AUC values for the first phase	21429	21735	The mean normalized AUC values for subjects treated with placebo or BBIC at doses of 800, 1,200, 1,600 or 2,000 CI units were 1.00±0.13, 1.08±0.31, 1.60±0.27, 2.53±0.27 and 2.03±0.34, respectively (Fig. 4). The difference among the treatment groups was statistically significant (P=0.006 by one-way ANOVA).
Bowman-Birk inhibitor concentrate (BBIC)	placebo	The mean normalized area under the curve (AUC) values for the second phase	21934	22225	The mean normalized AUC values for the subjects treated with placebo or BBIC at doses of 800, 1,200, 1,600 or 2,000 CI units were 1.00±0.24, 0.91±0.39, 1.51±0.29, 1.39±0.12 and 1.49±0.33, respectively (Fig. 4), and the difference was not statistically significant (P=0.446 by one-way ANOVA).
